Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Carbonic anhydrase IX in the prediction of right ventricular dysfunction in patients with hemodynamically stable acute pulmonary embolism.

Abul Y, Ozsu S, Mentese A, Durmus I, Bektas H, Pehlivanlar M, Turan OE, Sumer A, Orem A, Ozlu T.

Clin Appl Thromb Hemost. 2014 Nov;20(8):838-43. doi: 10.1177/1076029613486540. Epub 2013 Apr 23.

PMID:
23613041
2.

Usefulness of cardiac biomarkers in the prediction of right ventricular dysfunction before echocardiography in acute pulmonary embolism.

Choi HS, Kim KH, Yoon HJ, Hong YJ, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC, Kang JC.

J Cardiol. 2012 Dec;60(6):508-13. doi: 10.1016/j.jjcc.2012.07.006. Epub 2012 Aug 17.

3.

C-reactive protein in acute pulmonary embolism.

Abul Y, Karakurt S, Ozben B, Toprak A, Celikel T.

J Investig Med. 2011 Jan;59(1):8-14.

PMID:
21218608
4.

Combined risk stratification with computerized tomography /echocardiography and biomarkers in patients with normotensive pulmonary embolism.

Ozsu S, Karaman K, Mentese A, Ozsu A, Karahan SC, Durmus I, Oztuna F, Kosucu P, Bulbul Y, Ozlu T.

Thromb Res. 2010 Dec;126(6):486-92. doi: 10.1016/j.thromres.2010.08.021.

PMID:
20920821
5.

N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism.

Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, Konstantinides S.

Circulation. 2005 Sep 13;112(11):1573-9. Epub 2005 Sep 6.

6.

Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction.

Henzler T, Roeger S, Meyer M, Schoepf UJ, Nance JW Jr, Haghi D, Kaminski WE, Neumaier M, Schoenberg SO, Fink C.

Eur Respir J. 2012 Apr;39(4):919-26. doi: 10.1183/09031936.00088711. Epub 2011 Sep 29.

7.

The role of NT-proBNP and Apelin in the assessment of right ventricular dysfunction in acute pulmonary embolism.

Celik Y, Yardan T, Baydin A, Demircan S.

J Pak Med Assoc. 2016 Mar;66(3):306-11.

8.

Helical computerized tomography and NT-proBNP for screening of right ventricular overload on admission and at long term follow-up of acute pulmonary embolism.

Laiho MK, Harjola VP, Graner M, Piilonen A, Raade M, Mustonen P.

Scand J Trauma Resusc Emerg Med. 2012 May 4;20:33. doi: 10.1186/1757-7241-20-33.

10.

Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism.

Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartière JM, Chavelas C, Bonnin F, Stievenart JL, Solal AC.

Intensive Care Med. 2007 Feb;33(2):286-92. Epub 2006 Dec 13.

PMID:
17165016
11.

Regional right ventricular dysfunction in acute pulmonary embolism: relationship with clot burden and biomarker profile.

Tuzovic M, Adigopula S, Amsallem M, Kobayashi Y, Kadoch M, Boulate D, Krishnan G, Liang D, Schnittger I, Fleischmann D, McConnell MV, Haddad F.

Int J Cardiovasc Imaging. 2016 Mar;32(3):389-98. doi: 10.1007/s10554-015-0780-1. Epub 2015 Oct 1.

PMID:
26428674
12.

N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism.

Pruszczyk P, Kostrubiec M, Bochowicz A, Styczyński G, Szulc M, Kurzyna M, Fijałkowska A, Kuch-Wocial A, Chlewicka I, Torbicki A.

Eur Respir J. 2003 Oct;22(4):649-53.

13.

Natriuretic peptides in acute pulmonary embolism: a systematic review.

Cavallazzi R, Nair A, Vasu T, Marik PE.

Intensive Care Med. 2008 Dec;34(12):2147-56. doi: 10.1007/s00134-008-1214-5. Epub 2008 Jul 15. Review.

PMID:
18626627
14.

Natriuretic peptide type-B can be a marker of reperfusion in patients with pulmonary thromboembolism subjected to invasive treatment.

Andresen M, González A, Mercado M, Díaz O, Meneses L, Fava M, Córdova S, Castro R.

Int J Cardiovasc Imaging. 2012 Mar;28(3):659-66. doi: 10.1007/s10554-011-9857-7. Epub 2011 Apr 12.

PMID:
21480001
15.

Right ventricular dysfunction in hemodynamically stable patients with acute pulmonary embolism.

Keller K, Beule J, Schulz A, Coldewey M, Dippold W, Balzer JO.

Thromb Res. 2014 Apr;133(4):555-9. doi: 10.1016/j.thromres.2014.01.010. Epub 2014 Jan 14.

PMID:
24461144
16.

Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism.

Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Kuhnert K, Hasenfuß G, Pruszczyk P, Konstantinides S.

Eur Respir J. 2014 Jun;43(6):1669-77. doi: 10.1183/09031936.00211613. Epub 2014 Mar 13.

17.

Comparison of biomarkers for predicting disease severity and long-term respiratory prognosis in patients with acute pulmonary embolism.

Ohigashi H, Haraguchi G, Yoshikawa S, Sasaki T, Kimura S, Inagaki H, Hachiya H, Hirao K, Isobe M.

Int Heart J. 2010;51(6):416-20.

18.

N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism.

Alonso-Martínez JL, Urbieta-Echezarreta M, Anniccherico-Sánchez FJ, Abínzano-Guillén ML, Garcia-Sanchotena JL.

Am J Med Sci. 2009 Feb;337(2):88-92. doi: 10.1097/MAJ.0b013e318182d33e.

PMID:
19214022
19.

No firm association between N-terminal pro-brain natriuretic peptide and percentage of pulmonary vascular obstruction in patients with acute pulmonary embolism.

Agterof MJ, Schutgens RE, Verzijlbergen JF, van Buul MM, Tromp EA, Eijkemans MJ, van der Griend R, Biesma DH.

Thromb Res. 2011 Jun;127(6):547-50. doi: 10.1016/j.thromres.2011.02.014. Epub 2011 Mar 21.

PMID:
21421260
20.

[Biohumoral markers and right ventricular dysfunction in acute pulmonary embolism: the answer to thrombolytic therapy].

Enea I, Ceparano G, Mazzarella G, Di Sarno R, Cangiano G, Busino CA.

Ital Heart J Suppl. 2004 Jan;5(1):29-35. Italian.

PMID:
15253142

Supplemental Content

Support Center